VTR Earnings Prediction
The chart below shows how VTR performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VTR sees a -1.21% change in stock price 10 days leading up to the earnings, and a +1.00% change 10 days following the report. On the earnings day itself, the stock moves by -0.16%. This data can give you a slight idea of what to expect for the next quarter's release.
VTR Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
1.24B
7.52%
2.94%
Gross Margin
18.96%
12.26%
1.55%
Operating Margin
16.12%
15.23%
3.80%
Net Margin
1.70%
128.10%
-3.41%
EPS
0.05
127.78%
0.00%
No Data Available
VTR Earnings Analysis
Ventas, Inc. Corporation (VTR.N) Earnings Conference Call
Positive
Normalized FFO Growth: Ventas delivered $0.80 of normalized FFO per share in the third quarter, reflecting a 7% year-over-year increase driven by occupancy and revenue outperformance.
Cash NOI Growth: SHOP generated 15% year-over-year cash NOI growth, contributing to total same-store cash NOI growth of nearly 8%.
NOI Growth and Margin Expansion: Year-to-date, SHOP NOI has increased nearly 16%, with a RevPOR and OpExPOR spread of 300 basis points, leading to margin expansion.
Senior Housing Investment Growth: Ventas ramped up investments in senior housing to $1.7 billion this year, with expectations for SHOP NOI to increase by 12 percentage points and senior housing to grow to well over half of the business by year-end.
Increased FFO Guidance: The company raised its 2024 normalized FFO per share guidance, now expecting a midpoint of $3.16, driven by increased investment activity and higher SHOP same-store growth expectations.
Negative
Net Income Decline: 1. Declining Net Income: Ventas reported a net income attributable to common stockholders of only $0.05 per share in Q3 2024, indicating a significant decline compared to previous quarters.
Outpatient Medical Performance Decline: 2. Underwhelming Outpatient Medical Growth: The Outpatient Medical & Research segment's same-store cash NOI increased by only 2% in Q3 2024, which is considerably lower than the overall company average of 7.6%.
Debt to EBITDA Concerns: 3. High Debt Levels: The company's net debt to EBITDA ratio stands at 6.3x, which is still above the targeted range of 5x to 6x, indicating a concerning level of leverage.
Outpatient Occupancy Challenges: 4. Limited Occupancy Growth in Outpatient Medical: Despite improvements, the outpatient medical same-store occupancy only improved by 20 basis points year-over-year, reflecting a sluggish recovery in this segment.
Stock Performance Dilution: 5. Dilutive Impact from Stock Performance: The strong stock price performance has had a dilutive impact of $0.01 on normalized FFO guidance, highlighting challenges in maintaining earnings per share growth amidst rising equity valuations.
VTR FAQs
How does VTR typically perform around its earnings report dates?
Is Ventas, Inc. (VTR) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
VTR Earning Call Sentiment
Ventas, Inc. (VTR) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
VTR.N
-1.15%Positive
The earnings call summary reveals strong financial performance, with notable growth in NOI, occupancy, and revenue. The Q&A section highlights management's focus on senior housing investments and positive market conditions, despite some unclear responses. The increased FFO guidance and strong NOI growth expectations further support a positive outlook. Considering these factors, along with the absence of any significant negative catalysts, the stock price is likely to experience a positive movement in the next two weeks.
